Shantel
Key Takeaways:
- Genmed, a leading provider of vendor-neutral managed services to the NHS, appoints Jolene Rayner as chief executive officer.
- Jolene Rayner, formerly Chief Operations Officer at Genmed, brings extensive experience and a deep understanding of the company’s operations.
- Genmed’s innovative model supports NHS Trusts throughout the procurement cycle, resulting in significant cost savings and increased clinical productivity.
- Rayner’s leadership aims to further innovate and expand services, aligning with the evolving needs of the health system.
A New Chapter at Genmed: Jolene Rayner Takes the Helm:
Genmed, a prominent provider of vendor-neutral managed services to the National Health Service (NHS), has made a strategic move by appointing Jolene Rayner as its chief executive officer. Rayner’s journey within the company has been marked by her dedication and remarkable contributions. Having served as Chief Operations Officer and joining Genmed in 2013 as an area manager focused on pathology-related business, Rayner has played a pivotal role in shaping the company’s growth trajectory.
A Catalyst for Growth and Innovation:
Rayner’s appointment comes on the heels of her substantial impact within the organization. Her journey within Genmed has seen her rise through various senior roles, displaying an unparalleled commitment to innovation and strategic leadership. Working closely with NHS Trusts, Rayner has played a pivotal role in the introduction of new managed services encompassing diverse clinical disciplines, including pathology, renal care, surgery, and endoscopy. This strategic approach has been instrumental in propelling Genmed’s revenues from £5 million when she joined in 2013 to an impressive £100 million today.
Revolutionizing NHS Procurement: A Holistic Approach:
Genmed operates as a comprehensive partner to NHS Trusts, providing end-to-end support throughout the procurement cycle. Its services encompass financing, vendor selection, pricing optimization, inventory management, and invoice processing, thereby streamlining the procurement process. This holistic model is particularly impactful in the context of cost pressures within the health service. Genmed’s managed services have not only delivered substantial Cost Improvement Programme benefits to the NHS but also generated efficiency gains and VAT recovery. With HMRC-compliant managed services, Genmed enables Trusts to reclaim 20% VAT, freeing up funds for frontline services and patient care.
An Expanding Footprint: Transforming the NHS Landscape:
Today, Genmed’s influence extends to over 40 NHS Trusts and Health Boards across the UK, managing an array of contracts. This significant reach underscores the company’s pivotal role in enhancing the operational efficiency of the NHS while simultaneously driving cost savings. Genmed’s commitment to supporting the health system is further highlighted by its ability to deliver innovative solutions that align with evolving healthcare needs.
Jolene Rayner’s Vision for the Future:
Speaking about her appointment, Jolene Rayner emphasizes her dedication to the NHS and its patients. She shares, “As CEO, I’ll be working to grow our business and make Genmed a great place to work, however, the NHS and patients are at the very heart of everything we do. A key focus will be continuing to innovate and expand the range of services offered to align and further support our health system, so it’s an exciting time for me to be taking on this role.”
Praise from the Leadership:
Robin Modak, Genmed’s founder and chairman, lauds Rayner’s expertise and vision, highlighting her role in guiding the company’s evolution. Modak states, “Jolene has tremendous vision, is a great communicator and understands the company and our services inside and out, having worked at all levels and areas in the business. She’s a true leader and exactly the right person to lead the company to its next stage of development.”
A Promising Future for Genmed:
Jolene Rayner’s appointment as CEO of Genmed heralds a new chapter of growth and innovation for the company. Rayner’s deep understanding of the company’s operations, combined with her commitment to the NHS’s core values, is poised to drive Genmed’s continued success. With a keen focus on innovation and the evolving needs of the health system, Genmed’s future under Rayner’s leadership promises to be one of transformative impact.
